Antipsychotic-like Effects of Jobelyn® in Ketamine-induced Psychosis in Mice

• Adrian Itivere Omogbiya

  Department of Pharmacology, Faculty of Allied Health Sciences, Delta State University, Abraka, Nigeria

  Author

• Benneth Ben-Azu

  Department of Pharmacology, Faculty of Allied Health Sciences, Delta State University, Abraka, Nigeria

  Author

• Maxwell Oboh

  Delsu Joint Canadia-Isreal Neuroscience Laboratory, Department of Pharmacology, Faculty of Allied Health Sciences, Delta State University, Abraka, Nigeria

  Author

• Augustina Oghenevwaerhe Jewo

  Department of Microbiology, Faculty of Sciences, Delta State University, Abraka, Nigeria

  Author

• Oruese Orovwigho

  Department of Pharmacology, Faculty of Allied Health Sciences, Delta State University, Abraka, Nigeria

  Author

• Benjamin Oritsemuelebi

  Department of Pharmacology, Faculty of Allied Health Sciences, Delta State University, Abraka, Nigeria

  Author

• Edith Omozefe Okoro

  Department of Medical Laboratory Science, Faculty of Allied Health Sciences, Delta State University, Abraka, Nigeria

  Author

• Priestley E. Bamitale

  Department of Pharmacology, Faculty of Allied Health Sciences, Delta State University, Abraka, Nigeria

  Author

• James Ozakieoniso Kemelayefa

  Department of Pharmacology and Toxicology, Faculty of Pharmacy, Niger Delta University, Wilberforce Island, Bayelsa, Nigeria

  Author

• Ejiro Prosper Awhin

  Department of Medical Biochemistry, Faculty of Basic Medical Sciences, Delta State University, Abraka, Nigeria.

  Author

Background: Jobelyn® (JB) is a polyherbal formulation with proven benefits on psychosis, a psychiatric disorder, validated in dopamine-agonist models. However, its effect in ketamine, a glutamate antagonist, is linked to schizophrenia's pathology due to N-methyl-D-aspartate (NMDA) receptor hypofunction, which remains largely unknown. Hence, this study investigates the antipsychotic effectsof JB in ketamine-induced mouse models.

Methods: Antipsychotic activity of Jobelyn®(JB) (5, 10, and 50 mg/kg, p.o.) was assessed based on the inhibition of stereotyped behaviour induced by ketamine and ketamine-induced hyperactivity in mice. Ketamine-enhanced immobility in forced swim test (FST) and drug-induced ptosis and catalepsy in mice were also used to further evaluate JB's antipsychotic properties and its potential to cause extrapyramidal side effects.

Results: JB (5, 10, and 50 mg/kg, p.o.) significantly (p<0.05) inhibited stereotypy induced by apomorphine (1 mg/kg, i.p.) or ketamine (10 mg/kg, i.p.) and ketamine-induced hyperactivity. Furthermore, JB significantly (p<0.05) reduced the ketamine-induced enhancementofimmobility (30 mg/kg, i.p.) in mice, suggesting antipsychotic activity. JB also dose-independently depleted the monoamine as indexed by the ptosis paradigm. However, JB (5, 10, and 50 mg/kg, p.o.) did not cause cataleptic behaviour, as it failed to alter the duration of stay of the animals on the inclined plane.

Conclusion: This study provides valuable evidence that JB contains biologically active constituent with antipsychotic properties. The behavioural findings suggest possible modulation of dopaminergic and glutamatergic pathways, thus justifying its ethnomedicinal claims in the management of psychotic disorders.

1. Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, McGrath JJ, Whiteford HA. Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016. Schizophr Bull. 2018; 44(6):1195-203. DOI: https://doi.org/10.1093/schbul/sby058

2. Marder SR, Cannon TD. Schizophrenia. N Engl J Med. 2019; 381(18): 1753-61. DOI: https://doi.org/10.1056/NEJMra1808803

3. Vita A, Gaebel W, Mucci A. Negative symptoms of schizophrenia: past, present, and future. CNS Spectr. 2022; 27(4): 399-402.

4. Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bächer S, Cipriani A, Geddes JR, Salanti G, Davis JM. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927-42. DOI: https://doi.org/10.1176/appi.ajp.2017.16121358

5. Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine V. first- and second-generation anti psychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5): 385-392. DOI: https://doi.org/10.1192/bjp.bp.115.177261

6. Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, O'Donovan M, Correll CU, Kane JM, van Os J, Insel TR. Schizophrenia. Nat. Rev. Dis. Primers. 2018; 1: 15067. DOI: https://doi.org/10.1038/nrdp.2015.67

7. Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder. J Clin Psychopharmacol. 2017; 37(2): 138-147. DOI: https://doi.org/10.1097/JCP.0000000000000665

8. Ben-Azu B, Fokoua AR, Annafi OS, Adebayo OG, Del Re EC, Okuchukwu N, Aregbesola GJ, Ejenavi AC, Isiwele DM, Efezino AJ, Okpu ID. Effective action of silymarin against ketamine-induced schizophrenia in male mice: Insight into the biochemical and molecular mechanisms of action. J Psychiatr Res. 2024; 179: 141-155. DOI: https://doi.org/10.1016/j.jpsychires.2024.09.003

9. Howes OD, McCutcheon R, Owen MJ, Murray RM. The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry. 2017; 81(1):9-20. DOI: https://doi.org/10.1016/j.biopsych.2016.07.014

10. McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci. 2019; 42(3): 205-220. DOI: https://doi.org/10.1016/j.tins.2018.12.004

11. Snyder MA, Gao WJ. NMDA receptor hypofunction for schizophrenia revisited: perspectives from epigenetic mechanisms. Schizophr Res. 2020; 217: 60-70. DOI: https://doi.org/10.1016/j.schres.2019.03.010

12. Balu DT. The NMDA receptor and schizophrenia: from pathophysiology to treatment. Adv Pharmacol. 2016; 76: 351-382. DOI: https://doi.org/10.1016/bs.apha.2016.01.006

13. Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res. 2014; 152(2-3): 325-332. DOI: https://doi.org/10.1016/j.schres.2013.12.013

14. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther. 2014; 128(3): 419-432. DOI: https://doi.org/10.1016/j.pharmthera.2010.07.004

15. Winship IR, Dursun SM, Baker GB, Balista PA, Kandratavicius L, Maia-de-Oliveira JP, Hallak J, Howland JG. An overview of animal models related to schizophrenia. Can J Psychiatry. 2019; 64(1): 5-17. DOI: https://doi.org/10.1177/0706743718773728

16. Carlini EA, Contar JD, Silva-Filho AR, da Silveira-Filho NG, Frochtengarten ML, Bueno OF. Pharmacology of lemongrass (Cymbopogon citratus Stapf). I. Effects of teas prepared from the leaves on laboratory animals. J Ethnopharmacol. 2003; 17(1): 37-64. DOI: https://doi.org/10.1016/0378-8741(86)90072-3

17. Aderibigbe AO, Adaes SK, Adeoluwa OA, Omogbiya IA, Adeyemi OO. Antipsychotic property of hydromethanolic extract of seeds of Mucuna pruriens: evidence from animal studies. J Ethnopharmacol. 2017; 199: 68-75.

18. Adisa RA, Afolabi B, Obianwu HI, Omogbiya IA. Investigating the neuropharmacological properties of Sorghum bicolor leaf extract in rodents. West Afr J Pharmacol Drug Res. 2020; 35: 1-10.

19. Umukoro S, Aladeokin AC, Eduviere AT. Evaluation of the anti-aggressive and toxic effects of Sorghum bicolor leaf extract in mice. J Pharm Biol. 2015; 5(2) :109-114.

20. Girard AL, Awika JM. Sorghum polyphenols and other bioactive components as functional and health promoting food ingredients. J Cereal Sci. 2018; 84: 93-106. DOI: https://doi.org/10.1016/j.jcs.2018.10.009

21. Benson KF, Beaman JL, Ou B, Okubena A, Okubena O, Jensen GS. West African Sorghum bicolor leaf sheaths have anti-inflammatory and immune-modulating properties in vitro. J Med Food. 2013; 16(3):230-238. DOI: https://doi.org/10.1089/jmf.2012.0214

22. Dykes L, Rooney LW. Phenolic compounds in cereal grains and their health benefits. Cereal Foods World. 2016; 52(3): 105-111.

23. Omogbiya IA, Umukoro S, Aderibigbe AO, Bakre AG. Jobelyn pretreatment ameliorates symptoms of psychosis in experimental models. J Basic Clin Physiol Pharmacol. 2013; 24(4): 331-336. DOI: https://doi.org/10.1515/jbcpp-2012-0073

24. Javitt DC. Neurophysiological models for new treatment development in schizophrenia: early cortical sensory dysfunction. Ann N Y Acad Sci. 2015; 1344(1): 92-104. DOI: https://doi.org/10.1111/nyas.12689

25. Ben-Azu B, Aderibigbe AO, Omogbiya IA, Ajayi AM, Iwalewa EO. Morin Pretreatment Attenuates Schizophrenia-Like Behaviors in Experimental Animal Models. Drug Res (Stuttg). 2018; 68(3): 159-167. DOI: https://doi.org/10.1055/s-0043-119127

26. Chindo BA, Adzu B, Yahaya TA, Gamaniel KS. Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 38(2): 310-316. DOI: https://doi.org/10.1016/j.pnpbp.2012.04.018

27. Jain NK, Kulkarni SK, Singh A. Lipopolysaccharide-mediated immobility in mice: modulation by various drugs. Methods Find Exp Clin Pharmacol. 2003; 25(6): 441-5.

28. Ben-Azu B, Aderibigbe AO, Adeoluwa OA, Iwalewa EO. Antipsychotic property of the ethanol extract of Terminalia ivorensis stem bark in mice [unpublished MSc thesis]. Ibadan: University of Ibadan; 2015.

29. Porsolt RD, Moser PC, Castagne V. Behavioral indices in antipsychotic drug discovery. J Pharmacol Exp Ther. 2010; 333(3): 632-638. DOI: https://doi.org/10.1124/jpet.110.166710

30. Jimenez-Trevino L, Blasco-Fontecilla H, Braquehais MD, Baca-Garcia E. Ketamine for treatment-resistant depression: focus on the predictors of response. Curr Psychiatry Rep. 2015; 17(12): 95.

31. Monte AS, de Souza GC, McIntyre RS, Soczynska JK, dos Santos JV, Cordeiro RC, Ribeiro BM, de Lucena DF, Vasconcelos SM, de Sousa FC, Carvalho AF, Macêdo DS. Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: possible involvement of antioxidant and nitrergic pathways. J Psycho pharmacol. 2013; 27(11): 1032-1043. DOI: https://doi.org/10.1177/0269881113503506

32. Ben-Azu B, Aderibigbe AO, Ajayi AM, Iwalewa EO. Protective role of morin against ketamine-induced schizophrenia-like behaviors and oxidative damage in mice. Drug Metab. Pers. Ther. 2019; 34(3): 20180022.

33. Benturquia N, Coutureau E, Ettaoussi M, Cador M, Caille S. Dopaminergic and glutamatergic systems in motivated behaviors: role of striatal subregions. Prog Neuropsychopharmacol Biol Psychiatry. 2019; 89: 291-300.

34. Mahmoudi N, Kiasalari Z, Rahmani T, Sanaierad A, Afshin-Majd S, Naderi G, Baluchnejadmojarad T, Roghani M. Diosgenin Attenuates Cognitive Impairment in Streptozotocin-Induced Diabetic Rats: Underlying Mechanisms. Neuropsychobiology. 2021; 80(1): 25-35. doi: 10.1159/000507398. DOI: https://doi.org/10.1159/000507398

35. Moghaddam B, Krystal JH. Capturing the angel in angel dust: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull. 2012; 38(5): 942-949. DOI: https://doi.org/10.1093/schbul/sbs075

36. Bhattacharyya S, Bhattacharya SK. Glutamate-dopamine interaction and its implications in neuropsychiatric disorders. Indian J Exp Biol. 2016; 54(10): 627-634.

37. Frohlich J, Van Horn JD. Reviewing the ketamine model for schizophrenia. J Psychopharmacol. 2014; 28(4): 287-302. DOI: https://doi.org/10.1177/0269881113512909

38. Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A, Leucht S. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018; 268(7):625-39. DOI: https://doi.org/10.1007/s00406-018-0869-3

39. Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015; 41(4): 892-899. DOI: https://doi.org/10.1093/schbul/sbu170

40. Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, Gregory CJ, Haddad PM, Howes OD, Jones I, Joyce EM, Lewis S, Lingford-Hughes A, MacCabe JH, Owens DC, Patel MX, Sinclair JM, Stone JM, Talbot PS, Upthegrove R, Wieck A, Yung AR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020; 34(1): 3-78. DOI: https://doi.org/10.1177/0269881119889296

41. Cornel WA, Granger DA, Thibodeau EA. Assessment of salivary alpha-amylase and cortisol in association with behavioral inhibition in preschoolers. Dev Psychobiol. 2010; 52(8): 784-790.

42. Costall B, Naylor RJ. On the mode of action of apomorphine. Eur J Pharmacol. 1974;29(2):206-22. DOI: https://doi.org/10.1016/0014-2999(74)90019-3

43. Leite JV, Guimarães FS, Moreira FA. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol. 2008; 578(2-3): 222-7. doi: 10.1016/j.ejphar.2007.09.016. DOI: https://doi.org/10.1016/j.ejphar.2007.09.016

44. Awika JM, Rooney LW. Sorghum phytochemicals and their potential impact on human health. Phyto chemistry. 2004; 65(9): 1199- 1221. DOI: https://doi.org/10.1016/j.phytochem.2004.04.001

45. Heo HJ, Lee CY. Protective effects of quercetin and vitamin C against oxidative stress-induced neuro degeneration. J Agric Food Chem. 2004; 52(25): 7514-7517. DOI: https://doi.org/10.1021/jf049243r

46. Tungmunnithum D, Thongboonyou A, Pholboon A, Yangsabai A. Flavonoids and other phenolic compounds from medicinal plants for pharmaceutical and medical aspects: an overview. Medicines (Basel). 2018; 5(3): 93. DOI: https://doi.org/10.3390/medicines5030093

• PDF